Compare Stocks: CTOR, SION, ABEO, and UPB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.43 +0.4%	$6.38	$4.00 ▼ $7.65	$309.65M	1.33	1.11 million shs	1.42 million shs
CTOR Citius Oncology	$0.94 +2.5%	$0.73	$0.49 ▼ $2.25	$85.31M	3.52	64,228 shs	69,169 shs
SION Sionna Therapeutics	$8.26 +5.2%	$25.55	$4.01 ▼ $54.97	$354.92M	0.89	1.37 million shs	1.21 million shs
UPB Upstream Bio	$5.81 +1.4%	$6.78	$5.65 ▼ $33.68	$313.84M	1.28	592,324 shs	491,023 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+0.37%	-9.50%	-9.35%	-3.89%	-15.55%
CTOR Citius Oncology	+2.45%	+9.30%	+3.32%	+42.32%	-50.79%
SION Sionna Therapeutics	+5.22%	+15.04%	+27.86%	-76.23%	-63.82%
UPB Upstream Bio	+1.40%	-3.33%	-17.82%	-1.86%	-66.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.43 +0.4%	$6.38	$4.00 ▼ $7.65	$309.65M	1.33	1.11 million shs	1.42 million shs
CTOR Citius Oncology	$0.94 +2.5%	$0.73	$0.49 ▼ $2.25	$85.31M	3.52	64,228 shs	69,169 shs
SION Sionna Therapeutics	$8.26 +5.2%	$25.55	$4.01 ▼ $54.97	$354.92M	0.89	1.37 million shs	1.21 million shs
UPB Upstream Bio	$5.81 +1.4%	$6.78	$5.65 ▼ $33.68	$313.84M	1.28	592,324 shs	491,023 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	+0.37%	-9.50%	-9.35%	-3.89%	-15.55%
CTOR Citius Oncology	+2.45%	+9.30%	+3.32%	+42.32%	-50.79%
SION Sionna Therapeutics	+5.22%	+15.04%	+27.86%	-76.23%	-63.82%
UPB Upstream Bio	+1.40%	-3.33%	-17.82%	-1.86%	-66.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.33	Hold	$19.33	256.05% Upside
CTOR Citius Oncology	2.33	Hold	$6.00	538.30% Upside
SION Sionna Therapeutics	2.00	Hold	$42.22	411.16% Upside
UPB Upstream Bio	2.43	Hold	$29.67	410.61% Upside

Current Analyst Ratings Breakdown

Latest CTOR, SION, ABEO, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/31/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	ABEO Abeona Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00 ➝ $21.00
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/11/2026	UPB Upstream Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00
8/10/2026	SION Sionna Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	SION Sionna Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	SION Sionna Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	53.35	N/A	N/A	$2.94 per share	1.85
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.54 per share	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	$6.88 per share	N/A
UPB Upstream Bio	$2.85M	111.65	N/A	N/A	$6.29 per share	0.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
SION Sionna Therapeutics	-$75.27M	-$2.18	N/A	N/A	N/A	N/A	-32.94%	-31.08%	N/A
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest CTOR, SION, ABEO, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/6/2026	Q2 2026	SION Sionna Therapeutics	-$0.64	-$0.66	-$0.02	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
SION Sionna Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
CTOR Citius Oncology	0.25	0.73	0.34
SION Sionna Therapeutics	N/A	20.05	20.05
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CTOR Citius Oncology	70.52%
SION Sionna Therapeutics	N/A
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
CTOR Citius Oncology	9.82%
SION Sionna Therapeutics	5.10%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.85 million	N/A
SION Sionna Therapeutics	59	45.21 million	42.91 million	N/A
UPB Upstream Bio	75	54.77 million	45.76 million	N/A

CTOR, SION, ABEO, and UPB Headlines

Recent News About These Companies

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

HC Wainwright Forecasts Reduced Earnings for Upstream Bio

September 6, 2026 | americanbankingnews.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Upstream Bio (NASDAQ:UPB)

September 4, 2026 | americanbankingnews.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?

June 23, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTOR, SION, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.43 +0.02 (+0.37%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$5.44 +0.02 (+0.28%)

As of 09/14/2026 07:30 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Citius Oncology NASDAQ:CTOR

$0.94 +0.02 (+2.45%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+0.53%)

As of 09/14/2026 07:30 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Sionna Therapeutics NASDAQ:SION

$8.26 +0.41 (+5.22%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$7.92 -0.35 (-4.18%)

As of 09/14/2026 07:56 PM Eastern

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.

Upstream Bio NASDAQ:UPB

$5.81 +0.08 (+1.40%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$5.80 0.00 (-0.09%)

As of 09/14/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, SION, ABEO, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, SION, ABEO, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, SION, ABEO, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, SION, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Citius Oncology NASDAQ:CTOR

Sionna Therapeutics NASDAQ:SION

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTOR, SION, ABEO, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTOR, SION, ABEO, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTOR, SION, ABEO, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTOR, SION, ABEO, and UPB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Citius Oncology NASDAQ:CTOR

Sionna Therapeutics NASDAQ:SION

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools